CAJ | 학술논문

选择2006年12月至2008年6月入院的急性冠状动脉综合征(ACS)患者159例,分为经皮冠状动脉介入治疗(PCI)组和内科保守治疗组,两组患者再随机分为替罗非班治疗亚组和对照亚组,比较各亚组间48 h心电图改变、住院期间及随访30 d主要心血管事件的发生率及出血的发生率等.结果示两组中替罗非班亚组心电图均明显改善(P＜0.01);内科保守治疗组中替罗非班亚组随访30 d主要心血管事件发生率较对照亚组显著降低(P＜0.05),出血发生率两组差异无统计学意义(P＞0.05).提示ACS患者使用替罗非班能进一步减少心肌缺血事件,且安全性好.
선택2006년12월지2008년6월입원적급성관상동맥종합정(ACS)환자159례,분위경피관상동맥개입치료(PCI)조화내과보수치료조,량조환자재수궤분위체라비반치료아조화대조아조,비교각아조간48 h심전도개변、주원기간급수방30 d주요심혈관사건적발생솔급출혈적발생솔등.결과시량조중체라비반아조심전도균명현개선(P＜0.01);내과보수치료조중체라비반아조수방30 d주요심혈관사건발생솔교대조아조현저강저(P＜0.05),출혈발생솔량조차이무통계학의의(P＞0.05).제시ACS환자사용체라비반능진일보감소심기결혈사건,차안전성호.
A total of 159 patients with acute coronary syndrome(ACS)were enrolled from December 2006 to June 2008 and divided into the percutaneous coronary intervention(PCI)group and the internal medicine treatment group.The participants in the two groups were further assigned to the Tirofiban or the placebo control group.The change in electrocardiograph within 48 hours,major adverse cardiac events (MACE)during hospital stay and 30 days' follow-up,and bleeding were compared between the sub-groups.As a result,in comparison with the placebo control groups,the Tirofiban sub-groups showed significant improvement in electrocardiography(P＜0.01).In the internal medicine treatment group,the rate of MACE during 30 days' follow-up was significantly decreased in patients treated with Tirofiban(P＜0.05),although no significant difference in bleeding rate was found.Our data suggest that Tirofiban may be safe and effective in the treatment of ACS.